Allogene Therapeutics, Inc. Common Stock
ALLOAllogene Therapeutics, Inc. is a biotechnology company focused on developing allogeneic CAR T cell therapies for cancer treatment. The company's approach utilizes donor-derived T cells to create off-the-shelf immunotherapies aimed at providing scalable and accessible options for patients with various hematologic malignancies and solid tumors. Founded in 2017, Allogene leverages gene editing technology to enhance the safety and efficacy of its therapies.
Company News
Allogene Therapeutics won an arbitration against Cellectis regarding CAR-T therapy development rights, securing full control of cemacabtagene ansegedleucel in the U.S., EU, and U.K., while the tribunal rejected Cellectis's financial claims and allegations.
Allogene Therapeutics won a favorable arbitration ruling with Cellectis, reconfirming full development and commercial control of cemacabtagene ansegedleucel (cema-cel) in the US, EU, and UK, with a path to acquire full global rights by 2026.
The U.S. CAR T-cell therapies market is expected to grow from USD 3.43 billion in 2026 to USD 42.61 billion by 2035, driven by rising cancer cases, research investments, and innovative therapeutic approaches.
Despite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.
Allogene Therapeutics presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma, showing promising results with a 31% confirmed response rate and durable responses in heavily pretreated patients.
